203 related articles for article (PubMed ID: 9326417)
1. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
[TBL] [Abstract][Full Text] [Related]
2. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow.
Hale DA; Gottschalk R; Fukuzaki T; Wood ML; Maki T; Monaco AP
Transplantation; 1997 Feb; 63(3):359-64. PubMed ID: 9039923
[TBL] [Abstract][Full Text] [Related]
3. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1998 Feb; 65(4):473-9. PubMed ID: 9500619
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine.
Hale DA; Gottschalk R; Wood ML; Maki T; Monaco AP
Transplant Proc; 1996 Dec; 28(6):3270-1. PubMed ID: 8962270
[No Abstract] [Full Text] [Related]
5. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
[TBL] [Abstract][Full Text] [Related]
6. Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental rapamycin.
Dono K; Maki T; Wood ML; Monaco AP
Transplantation; 1995 Dec; 60(11):1268-73. PubMed ID: 8525521
[TBL] [Abstract][Full Text] [Related]
7. Extended skin allo- and xenograft survival in mice treated with rapamycin, antilymphocyte serum, and donor-specific bone marrow transfusion.
Hale DA; Gottschalk R; Fukuzaki T; Wood ML; Maki T; Monaco AP
Transplant Proc; 1996 Dec; 28(6):3269. PubMed ID: 8962269
[No Abstract] [Full Text] [Related]
8. Late adjunctive therapy with single doses of rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells.
De Fazio SR; Plowey JM; Hartner WC; Gozzo JJ
Transpl Immunol; 1996 Jun; 4(2):105-12. PubMed ID: 8843586
[TBL] [Abstract][Full Text] [Related]
9. Use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow in antilymphocyte serum-treated mice: the unique effect of sirolimus.
Hale D; Gottschalk R; Maki T; Monaco AP
Transplant Proc; 1998 Aug; 30(5):2432-4. PubMed ID: 9723527
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts.
Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
Transplant Proc; 1999; 31(1-2):1244. PubMed ID: 10083555
[No Abstract] [Full Text] [Related]
11. Protection of corneal allografts by CTLA4-Ig.
Gebhardt BM; Hodkin M; Varnell ED; Kaufman HE
Cornea; 1999 May; 18(3):314-20. PubMed ID: 10336035
[TBL] [Abstract][Full Text] [Related]
12. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig.
Bonham CA; Peng L; Liang X; Chen Z; Wang L; Ma L; Hackstein H; Robbins PD; Thomson AW; Fung JJ; Qian S; Lu L
J Immunol; 2002 Sep; 169(6):3382-91. PubMed ID: 12218160
[TBL] [Abstract][Full Text] [Related]
13. Effect of single-dose, late treatment with rapamycin on skin allograft survival in ALS- and donor bone marrow cell-treated mice.
De Fazio SR; Plowey J; Hartner WC; Gozzo JJ
Transplant Proc; 1994 Dec; 26(6):3102-3. PubMed ID: 7998084
[No Abstract] [Full Text] [Related]
14. Indefinite survival of skin allografts in adult thymectomized, antilymphocyte serum-treated mice given bone marrow and thymus grafts of donor origin: tolerance induction by donor bone marrow and thymus.
Fukuzaki T; Hancock WW; Monaco AP; Maki T
Transplantation; 1998 Apr; 65(8):1036-43. PubMed ID: 9583862
[TBL] [Abstract][Full Text] [Related]
15. A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts.
Li S; Thanikachalam M; Pang M; Kawaharada N; Aitouche A; Pham SM
Ann Thorac Surg; 2001 Oct; 72(4):1306-10. PubMed ID: 11603451
[TBL] [Abstract][Full Text] [Related]
16. Importance of schedule of administration of adjunctive, short-term immunosuppression in ALS- and bone marrow cell-treated, skin-allografted mice.
Gozzo JJ; Plowey J; Hartner WC; De Fazio SR
Transplant Proc; 1995 Feb; 27(1):169-70. PubMed ID: 7878958
[No Abstract] [Full Text] [Related]
17. Anti-CD40 therapy extends renal allograft survival in rhesus macaques.
Pearson TC; Trambley J; Odom K; Anderson DC; Cowan S; Bray R; Lin A; Hollenbaugh D; Aruffo A; Siadak AW; Strobert E; Hennigar R; Larsen CP
Transplantation; 2002 Oct; 74(7):933-40. PubMed ID: 12394833
[TBL] [Abstract][Full Text] [Related]
18. Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors.
Fu F; Li W; Lu L; Fung JJ; Thomson AW; Qian S
Transplant Proc; 1999; 31(1-2):453. PubMed ID: 10083185
[No Abstract] [Full Text] [Related]
19. Effect of rapamycin on islet and skin xenograft survival.
Bobbio SA; Porter JG; Monaco AP
Transplant Proc; 1993 Aug; 25(4):2745-6. PubMed ID: 8356733
[No Abstract] [Full Text] [Related]
20. Inhibition of corneal allograft reaction by CTLA4-Ig.
Hoffmann F; Zhang EP; Pohl T; Kunzendorf U; Wachtlin J; Bulfone-Paus S
Graefes Arch Clin Exp Ophthalmol; 1997 Aug; 235(8):535-40. PubMed ID: 9285225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
